[ad_1]
The estimated effectiveness of the monoclonal antibody drug nirsevimab was 89% against medically attended respiratory syncytial virus (RSV) infection and 93% against hospitalization among children younger than 5 years during the US 2023-24 respiratory …
|
Sources 2/ https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/estimates-nirsevimab-89-effective-against-rsv-kids-93-against The mention sources can contact us to remove/changing this article |
[ad_2]